ArticleBiology2023

Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer.

Rocío Jiménez Galán et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.